Stock Track | Jazz Pharmaceuticals Soars 5.53% in Pre-Market on Strong Q1 Earnings Beat and Reaffirmed Guidance

Stock Track

May 06

Jazz Pharmaceuticals PLC (JAZZ) saw its stock price soar 5.53% in pre-market trading on Wednesday.

The significant upward movement appears driven by the company's release of better-than-expected first-quarter 2026 financial results. Jazz Pharmaceuticals reported adjusted earnings per share of $6.34, substantially beating the analyst consensus estimate of $4.57. Quarterly revenue reached $1.07 billion, a 19% year-over-year increase that also surpassed expectations. The company highlighted strong growth from its key products, including Xywav, Epidiolex, and Zepzelca.

Furthermore, management reaffirmed its full-year 2026 revenue guidance of $4.25 billion to $4.5 billion, providing confidence in its ongoing financial trajectory. Following the earnings release, multiple analysts raised their price targets on the stock, reflecting increased optimism about the company's prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1119573924"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1119573924\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1119573924?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 17:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119573924","market":"hk","top_or_hot":-1,"title":"Stock Track | Jazz Pharmaceuticals Soars 5.53% in Pre-Market on Strong Q1 Earnings Beat and Reaffirmed Guidance","media":"Stock Track","content":"<p>Jazz Pharmaceuticals PLC (JAZZ) saw its stock price soar 5.53% in pre-market trading on Wednesday.</p><p>The significant upward movement appears driven by the company's release of better-than-expected first-quarter 2026 financial results. Jazz Pharmaceuticals reported adjusted earnings per share of $6.34, substantially beating the analyst consensus estimate of $4.57. Quarterly revenue reached $1.07 billion, a 19% year-over-year increase that also surpassed expectations. The company highlighted strong growth from its key products, including Xywav, Epidiolex, and Zepzelca.</p><p>Furthermore, management reaffirmed its full-year 2026 revenue guidance of $4.25 billion to $4.5 billion, providing confidence in its ongoing financial trajectory. Following the earnings release, multiple analysts raised their price targets on the stock, reflecting increased optimism about the company's prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Jazz Pharmaceuticals Soars 5.53% in Pre-Market on Strong Q1 Earnings Beat and Reaffirmed Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Jazz Pharmaceuticals Soars 5.53% in Pre-Market on Strong Q1 Earnings Beat and Reaffirmed Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 17:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jazz Pharmaceuticals PLC (JAZZ) saw its stock price soar 5.53% in pre-market trading on Wednesday.</p><p>The significant upward movement appears driven by the company's release of better-than-expected first-quarter 2026 financial results. Jazz Pharmaceuticals reported adjusted earnings per share of $6.34, substantially beating the analyst consensus estimate of $4.57. Quarterly revenue reached $1.07 billion, a 19% year-over-year increase that also surpassed expectations. The company highlighted strong growth from its key products, including Xywav, Epidiolex, and Zepzelca.</p><p>Furthermore, management reaffirmed its full-year 2026 revenue guidance of $4.25 billion to $4.5 billion, providing confidence in its ongoing financial trajectory. Following the earnings release, multiple analysts raised their price targets on the stock, reflecting increased optimism about the company's prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAZZ","symbol_name":"爵士制药","start_time":0,"source_url":"","article_id":"1119573924","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119573924","pubTimestamp":1778058912,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Jazz Pharmaceuticals PLC (JAZZ) saw its stock price soar 5.53% in pre-market trading on Wednesday.The significant upward movement appears driven by the company's release of better-than-expected...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JAZZ":"爵士制药"},"translate_title":"个股追踪|Jazz Pharmaceuticals盘前飙升5.53%，因Q1盈利强劲超出预期并重申指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":1},"content_text":"Jazz Pharmaceuticals PLC (JAZZ) saw its stock price soar 5.53% in pre-market trading on Wednesday.The significant upward movement appears driven by the company's release of better-than-expected first-quarter 2026 financial results. Jazz Pharmaceuticals reported adjusted earnings per share of $6.34, substantially beating the analyst consensus estimate of $4.57. Quarterly revenue reached $1.07 billion, a 19% year-over-year increase that also surpassed expectations. The company highlighted strong growth from its key products, including Xywav, Epidiolex, and Zepzelca.Furthermore, management reaffirmed its full-year 2026 revenue guidance of $4.25 billion to $4.5 billion, providing confidence in its ongoing financial trajectory. Following the earnings release, multiple analysts raised their price targets on the stock, reflecting increased optimism about the company's prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}